Background: Clinical trials in men with biochemically recurrent prostate cancer (BRPC) have been hampered by long survival times, making overall survival (OS) a difficult end point to reach. Intermediate end points are needed in order to conduct such trials within a more feasible time frame.
introduction
An estimated 241 740 cases of prostate cancer were diagnosed in the United States in 2012, with 28 170 of those individuals dying as a result of their disease [1] . The clinical course of patients with prostate cancer is varied, and while the majority of patients will be cured after local therapy, about 20%-40% will develop a prostate-specific antigen (PSA) recurrence by 10 years postprostatectomy [2, 3] . A similar proportion of those patients will develop distant metastases, accounting for the majority of the morbidity and mortality from this disease [3, 4] .
Defining the optimal treatment of men with PSA recurrence after local therapy has proven difficult. Management options for these men are numerous and include salvage pelvic irradiation (in select patients), continuous androgen deprivation therapy (ADT) initiated at the time of PSA recurrence, deferred ADT reserved until the onset of distant metastases, intermittent ADT, or clinical trial enrollment [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The lack of a standard treatment approach for these patients relates to the heterogeneity of this population, the existence of strong patient and physician preferences regarding the implementation of ADT, and the absence of well-conducted comparative clinical trials in these patients [3, 4, 9, 15] . Challenges in designing informative trials for men with PSA-recurrent prostate cancer abound, including the length of follow-up needed to assess clinically-relevant end points (e.g. metastasis and death), and the large sample sizes required to make statistically meaningful conclusions.
The need for surrogate end points is paramount for conducting trials in this patient population within a feasible time frame. We have previously described the natural history of patients with biochemically recurrent prostate cancer after radical prostatectomy in whom additional therapy was deferred until the development of radiographic metastases [4, 9, 16] . The objective of this analysis was to examine the association between metastasis-free survival (the time interval from PSA recurrence to first radiographic metastasis) and overall survival (the time interval from first metastasis to death). This study was not intended to develop a formal prediction model for overall survival (OS), but rather, serves as an important first step towards establishing MFS as a potential meaningful end point in future trials.
patients and methods patients
Among patients undergoing radical prostatectomy at Johns Hopkins Hospital between July 1981 and July 2010, 1973 men subsequently developed a biochemical recurrence (defined as a postoperative PSA of ≥0.2 ng/mL). Our cohort of interest was the subset who did not receive any additional adjuvant/neoadjuvant or salvage therapies before the development of radiographic metastases (N = 642). Of these, only 450 patients had sufficient clinical information to be included in the present analysis. Further details on this patient population are presented as online supplements. Follow-up data was collected through July 2012.
This was a retrospective analysis of prospectively collected data. Data was derived from the Johns Hopkins Master Prostatectomy Database which stores clinical, pathological, and demographic information under a consent waiver allowing its use for future research without disclosing patient identifiers [16] . This database is approved by the Johns Hopkins institutional review board, and meets the requirements of the Health Insurance Portability and Accountability Act.
Patients were generally followed post-prostatectomy with PSA evaluation and digital rectal examination every 3 months for the first year, every 6 months for the second year, and every 12 months thereafter. Upon biochemical recurrence, PSA was measured approximately every 3-6 months. No patient received ADT until after the development of metastases. Per the standard practices of the treating physicians, computed tomography (CT) and technetium-99 bone scans were typically conducted at baseline and then yearly (or sooner if symptoms warranted). Precise data regarding the frequency of imaging were not captured in the database. Variations in postoperative follow-up practices were largely a result of patients opting to be followed outside of Johns Hopkins. Metastatic disease was defined on imaging modalities, most often using CT or bone scan.
PSA doubling time (PSADT) following biochemical recurrence was calculated as previously described [15] . A minimum of two PSA measurements collected ≥3 months apart were required.
statistical analysis
The primary end point of this study was OS, defined as the interval from the date of the first radiographic metastasis to the date of death from any cause. MFS was defined as the interval from biochemical recurrence (PSA ≥0.2 ng/ml) to first metastasis. The cause of death was determined from death certificates, and was coded as 'prostate cancer related' or 'nonprostate cancer related'. The association of risk of death with MFS and other potential prognostic clinical factors were assessed first using univariate Cox proportional hazards models and then multivariable models. Unadjusted hazard ratios were computed together with 95% confidence intervals (CIs). Clinical factors that were considered in the model are listed in Table 1 . Log-transformation was applied to MFS to reduce skewness in its distribution. Time from prostatectomy to PSA relapse, PSADT, MFS, and number of metastases were considered both as continuous and binary variables. When transforming continuous variables to binary variables, optimized cut-off points were determined based on a modified log-rank test statistic [17, 18] . The cutpoints used for Gleason score, time from prostatectomy to PSA relapse, and PSADT were chosen based on previously published work [4, 16] .
For the multivariable analysis, a backward elimination technique was applied to select variables from all potential covariates; those with P-values ≤0.10 were retained in the final model. Bootstrapping was used to validate the model [19] . The predictive discrimination of the model was assessed using c-index [19] . Median MFS was estimated for the whole cohort of 450 men using the Kaplan-Meier method. Likewise, OS was estimated for the 140 men with metastases using the Kaplan-Meier method. Differences in OS were evaluated using the log-rank test.
All tests were two sided and considered statistically significant at P ≤ 0.05. Statistical analyses were carried out using software R (version 2.15.1, Bethesda, MD) and SAS (version 9.2, Cary, NC).
results
Of the 450 men with PSA-recurrent prostate cancer included in this analysis, 140 developed distant metastases. Median MFS was 10.4 years (95% CI 7.6-14.0 years). The disease characteristics of these 140 men are summarized in Table 1 . Metastases were most often to bone (124 patients; 88.6%). The remaining 16 patients (11.4%) developed metastases in extrapelvic lymph nodes (5.7%), lungs (3.6%), or liver (2.1%). The median PSA at the time of initial metastasis was 24.8 ng/ml (range, 0.2-798.5 ng/ml).
As of July 2012, 78 patients (55.7%) have died after a median follow-up of 5.5 years from the date of first metastasis. Seventyone deaths were due to metastatic prostate cancer; the other seven subjects died of other causes. Median OS was 6.6 years (95% CI 5.8-8.4 years) ( Figure 1A ). In univariate proportional hazards analysis, six variables were significantly associated with OS: MFS, PSADT after biochemical recurrence, number of metastases, site of metastases, pain with metastases, and bisphosphonate use after metastasis ( Table 2 ).
The multivariable model is presented in Table 3 . MFS (Logtransformed), number of metastases, pain with metastasis. and bisphosphonate use after metastasis were all found to independently associate with OS. Figure 1B -E depicts OS Kaplan-Meier curves stratified by these significant prognostic variables. The c-index calculated from the model was 0.72 (95% CI 0.65-0.80). After penalizing for possible overfitting using 200 bootstrap samples, the estimate of c-index was 0.64. Figure 2 shows a scatter plot examining the relationship between MFS and OS in the 78 men who died with metastatic prostate cancer.
discussion While a number of predictive survival models exist for men with noncastrate biochemically recurrent prostate cancer, to our knowledge this is the first multivariable model that shows a significant association between MFS and OS. The conduct of informative clinical trials in this patient population has been challenged by the long natural history of this disease and the lack of validated surrogate end points. We and others have shown that OS in these patients may average 20 years or more from the time of PSA recurrence, while MFS may average 10 years [4, 15, 16] . Even if focusing on patients at highest risk of metastasis and death (e.g. those with a PSADT of ≤9 months), median OS and MFS are still estimated at 8 and 3 years, respectively [4, 16] . As a result, establishing that a given therapy leads to an OS benefit in this patient population has historically been difficult.
In order to advance the field, meaningful and realistic trial end points for men with biochemically recurrent prostate cancer are needed. Our group and others have shown that PSA kinetics are among the strongest predictors of metastasis and death in these patients [3, 4, 16] . However, while baseline PSA kinetics can serve as an invaluable tool in risk-stratifying patients before trial enrollment, post-treatment changes in PSA kinetics remain far from a validated intermediate end point [15] . MFS might be a more attractive proximal end point to use when designing trials in these patients. Compared with OS, MFS occurs earlier and is not influenced by therapies given after the development of metastases. Two prior studies suggested a possible association between MFS and OS among men with PSA-recurrent prostate cancer [3, 9] . However, this association did not remain significant in multivariable models. The present analysis has the advantage of longer follow-up and more patients with established metastatic disease. Here, we present data suggesting a significant association between MFS and OS in men with biochemically recurrent prostate cancer after controlling for known prognostic variables.
In addition, our multivariable model also revealed that the number of metastases at first presentation, the presence/absence of pain at metastasis, and the use of bisphosphonates after metastasis were all associated with OS. These parameters have previously been associated with OS, not only in prostate cancer but in a range of other solid tumors [20, 21] . Interestingly, our current analysis did not reveal a significant association between Gleason score and OS, despite such an association having been suggested in some, but not all, prior studies [2, 22, 23] . This suggests that in a group of patients who have already developed metastases, Gleason grade may no longer be as relevant. Finally, our analysis did not show an independent association between PSADT and OS after accounting for other covariates (including MFS), perhaps due to the close interconnection between PSADT and MFS [4] .
It could be argued that the primary end point for trials targeting men with biochemically recurrent prostate cancer should have three characteristics, namely it should be: (i) clinically meaningful, (ii) occur in a reasonable time frame, and (iii) correlate with OS. It appears that MFS may fulfill all of these criteria. With the inherent pitfalls in designing studies in these patients, we need to be more thoughtful in choosing our end points. Investing in large phase III trials only to demonstrate that an intervention leads to favorable changes in PSA kinetics is not going to provide a great deal of clarity on how to manage these men, and it would therefore seem prudent to design future trials around more meaningful end point such as MFS. The current study is only the first step in potentially establishing MFS as a reasonable intermediate end point in such trials, and clearly falls short of satisfying surrogacy criteria. This study has several shortcomings. Despite this being the largest study of its kind, the sample size remains relatively small, with only 140 men developing metastasis and only 78 deaths. These small patient numbers have led to a relatively low precision when estimating hazard ratios, as evidenced by wide CIs (see Table 3 ). Secondly, because of the retrospective nature of this analysis, patients had treatment deferred until the time of overt metastasis in a nonrandom fashion. This could potentially lead to exclusion of patients with more aggressive disease. Furthermore, given that the management of these patients was not prospectively defined, variability in follow-up and the utilization of diagnostics (i.e. CT and bone scans) was surely present. PSA changes most likely led to imaging in many patients, which in turn may have led to detection bias. In addition, the number of non-Caucasian men included in the analysis is much lower than the true racial mix of patients with prostate cancer and may not be reflective of the general US population [24] . Last, this study is based on a single-institution experience and needs validation across multiple centers, ideally in a prospective manner.
In conclusion, using a cohort of men with biochemically recurrent prostate cancer following prostatectomy treated with deferred ADT (initiated after metastasis), we have shown that 
